echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Yangtze River Pharmaceutical's "Rigofinil Tablets" Launched on the First Domestic Newspaper

    Yangtze River Pharmaceutical's "Rigofinil Tablets" Launched on the First Domestic Newspaper

    • Last Update: 2021-07-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 19, the CDE official website showed that Yangtze River's 4-category generic drug "Rigofinil Tablets" was declared for listing (acceptance number: CYHS2101075), which was the first generic drug reported for listing in China
    .
    Its indications are: colorectal cancer, gastrointestinal stromal tumor, liver cancer

    .


    Data source: CDE official website


    Regorafenib is a new type of oral multi-kinase inhibitor, which is a new generation of oral multi-target tyrosine kinase inhibitor developed by Bayer after Sorafenib
    .
    In addition to inhibiting KIT and PDGFRA kinase targets, regorafenib can also act on RET, BRAF, RAF1, VEGFR, FGFR, PDGFRP and other targets

    .
    Regorafenib can block a variety of enzymes that promote tumor growth, and inhibit tumor formation, angiogenesis and tumor microenvironment formation by acting on multiple kinases on tumor cells, endothelial cells and peripheral cells

    .


    On September 27, 2012, the FDA approved it for the treatment of metastatic chemotherapy, anti-VEGF therapy, and anti-EGFR therapy (if KRAS wild-type) previously received or based on fluorouracil, oxaliplatin, and irinotecan.
    Patients with colorectal cancer (CRC)

    .


    On February 25, 2013, the FDA approved it for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) patients who had previously been treated with imatinib and sunitinib
    .


    On April 28, 2017, the FDA approved it for the second-line treatment of hepatocellular carcinoma (HCC) patients who have previously used Nexavar® (Sorafenib)
    .


    On March 24, 2013, the original CFDA approved its listing for the treatment of metastatic colorectal cancer (mCRC) that had previously received fluorouracil, oxaliplatin, and irinotecan-based chemotherapy and anti-EGFR treatment (RAS wild-type).
    ) Patients, and locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) patients who have previously been treated with imatinib mesylate and sunitinib malate

    .


    In May 2017, the original CFDA approved it for the treatment of metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumor (GIST)
    .


    On December 12, 2017, the original CFDA approved it for the treatment of liver cancer
    .


    According to the Insight database, the global sales of Rigofinil have been increasing year by year since its listing in 2012 (except for 2016), and its sales in 2019 reached 458 million U.
    S.
    dollars

    .


    Data source: insight database


    At present, in addition to the original research company Bayer, there are 21 pharmaceutical companies that have deployed rigorfenib.
    The companies involved include CSPC, CP Tianqing, Shuanglu, Qilu Pharmaceutical, Kelun, etc.
    ; among them, 5 companies are conducting BE experiments.
    Companies, 15 companies have applied for clinical trials

    .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.